Evidence Sheet: NVIDIA (NVDA)
The standing BullScope yardsticks for NVIDIA, computed from official filings and refreshed with each new edition.
Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.
The standing BullScope yardsticks for NVIDIA, computed from official filings and refreshed with each new edition.
In one breath NVIDIA's filed numbers show a business generating nearly $50 billion in free cash flow in a single...
In one breath Meta's ads business is growing faster than almost any company its size, with Q2 2026 revenue up...
The standing BullScope yardsticks for Amazon, computed from official filings and refreshed with each new edition.
Picture a warehouse the size of thirty football fields humming at 3 a.m., robots ferrying shelves to human pickers while,...
In one breath The filed numbers show Alphabet earning its fattest margins in a decade, with net income crossing $132...
A year ago, Microsoft was the world's most valuable company. Today, the stock sits nearly 24% below where it traded...
Goldman Sachs raised its Apple valuation estimate to $370 on July 27, 2026, citing anticipated outperformance on iPhone and Mac...
In one breath ExxonMobil's filed numbers show a business generating cash at a scale it hasn't matched in decades, and...
A company's stock sits 16% below its 52-week high. Its order book just hit an all-time record. Those two facts...
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer